达洛胺不干扰OATP介导的多塞塔克塞尔的吸收
Stefan A J Buck1, Zahra Talebi2, Thomas Drabison2
1Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
International journal of cancer
|March 16, 2024
概括
用于治疗前列腺癌的多塞塔克塞尔的达洛胺,不会影响患者的多塞塔克塞尔水平. 这项研究没有通过OATP1B3载体发现药物相互作用,支持转移性前列腺癌的联合治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药物相互作用 药物相互作用
背景情况:
- 转移性前列腺癌的治疗通常涉及dcetaxel.
- 达洛胺是一种被批准用于转移性前列腺癌的雄激素受体抑制剂,通常与多塞结合使用.
- 在前列腺瘤中,OATP1B3 载体促进了多塞塔克塞尔的吸收,并且在体外被达洛胺抑制.
研究的目的:
- 为了研究达罗胺在体内对多塞塔塞尔药理动学的影响.
- 评估通过OATP1B3载体抑制介导的潜在药物相互作用.
主要方法:
- 在体外测试以确定达洛胺的OATP1B3抑制.
- 使用患者衍生异种移植 (PDX) 模型进行体内研究,以评估dcetaxel瘤积累.
- 用达洛胺治疗的转移性前列腺癌患者的生物标志物分析.
主要成果:
- 在Cmax以上的度下,达洛胺在体外抑制了OATP1B3.
- 在体内,达洛胺没有改变Oatp1b基质的药理动力学,包括多塞.
- 在达洛胺的存在下,多塞塔塞尔瘤积累和OATP1B生物标志物水平保持不变.
结论:
- 达洛胺在体内或患者中没有显著抑制OATP1B3介导的运输.
- 达洛胺和多塞塔克塞尔之间没有发现基于OATP1B3载体的药物相互作用.
- 对于转移性前列腺癌的治疗,支持使用多塞塔克塞尔和达洛胺的联合治疗.
相关概念视频
Tissue-Drug Binding: Localization of Drugs and its Significance
80
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
80
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Drug Elimination by Renal Route: Tubular Reabsorption
3.4K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.4K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drug Elimination by Renal Route: Tubular Secretion
2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K


